12. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prev-
2. National Cancer Institute. SEER stat fact sheets: Corpus and uterus, NOS.
354:261–269.
30. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of
29. National Cancer Institute. SEER stat fact sheets: Corpus and uterus, NOS
242. 
400. 
280. 
407. 
329. 
35. Fanelli M, Canobbio S, Zucchi A, et al. PTEN in patients with Lynch syn-
33. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma sur-
32. Francis JH, Kleinerman RA, Seddon JM, et al. Increased risk of second-
31. Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associ-
25. Mendiol A, Schulzer K, Gelfand PA. Non-epithelial adenocarcinoma of the
24. Broadus RR. Pathology of Lynch syndrome–associated gynecological can-
cancers. In: Lu KH, ed. Hereditary Gynecologic Cancer: Risk, Prevention, and
18. Italia P, Rimon S, Zuckerman S, et al. Mutations of the PTEN tumor suppres-
5. Mendiol A, Schulzer K, Gelfand PA. Non-epithelial adenocarcinoma of the
4. Broadus RR. Pathology of Lynch syndrome–associated gynecological can-
cancers. In: Lu KH, ed. Hereditary Gynecologic Cancer: Risk, Prevention, and
3. National Cancer Institute. SEER stat fact sheets: Corpus and uterus, NOS.
2. National Cancer Institute. SEER stat fact sheets: Corpus and uterus, NOS.